Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
A real-life study on CPX-351 and the standard arm ('7 + 3') of the CPX-351 registrative trial in adults with secondary Acute Myeloid Leukemia were compared by an unanchored Matching-adjusted indirect comparison (MAIC), in order to evaluate the efficacy and toxicity of CPX-351. Results of this study are important to confirm the role of CPX-351 in significantly improving survival and remission rates compared with '7 + 3' with a good safety profile in AML patients with high-risk features, a target group traditionally with a very poor prognosis. Moreover, this pilot analysis underlines the potentiality of the statistical method to compare studies with strong differences.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12141356 | PMC |
| http://dx.doi.org/10.1007/s00277-025-06381-3 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Indirect Comparison of Epcoritamab Versus Axicabtagene Ciloleucel in Chimeric Antigen Receptor T-Cell-Eligible and -Naive Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma.
Clin Lymphoma Myeloma Leuk
July 2025
Université Paris Cité, Hôpital Saint Louis, Assistance Publique - Hôpitaux de Paris, Hemato-oncologie, Inserm U1153, Paris, France.
Background: In the absence of a head-to-head trial of off-the-shelf subcutaneous epcoritamab, a novel CD3xCD20 bispecific antibody, versus chimeric antigen receptor T-cell therapy (CAR T), a matching-adjusted indirect comparison (MAIC) of epcoritamab versus axicabtagene ciloleucel (axi-cel) efficacy was conducted in patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) with ≥ 2 prior lines of systemic therapy.
Methods: The MAIC used epcoritamab patient-level data from EPCORE NHL-1 (NCT03625037; April 2023 data cutoff) and axi-cel aggregated data from ZUMA-1 (NCT02348216). Patients without prior CAR T were matched to the ZUMA-1 population; weighted regression models were used to estimate absolute differences in overall response rate (ORR) and complete response (CR) rate, and weighted Cox proportional-hazards models were used to estimate hazard ratios (HRs) for progression-free survival (PFS) and overall survival (OS).
Matching-adjusted indirect comparison of ribociclib + nonsteroidal aromatase inhibitor versus abemaciclib + endocrine therapy in hormone receptor-positive/HER2-negative early breast cancer.
J Comp Eff Res
August 2025
Breast Cancer Research Unit, Mount Vernon Cancer Centre, Northwood, Middlesex, UK.
Ribociclib + nonsteroidal aromatase inhibitor (NSAI) and abemaciclib + endocrine therapy (ET) are approved for high-risk hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2-) early breast cancer based on data from the NATALEE and monarchE trials, respectively. No trials have directly compared efficacy and safety of adjuvant ribociclib and abemaciclib. This study compared relative efficacy and safety of adjuvant ribociclib + NSAI versus abemaciclib + ET using matching-adjusted indirect comparison (MAIC).
View Article and Find Full Text PDFBackground: Plaque psoriasis of the scalp, a common psoriasis location, remains difficult to manage. The comparative efficacy of newer oral agents, such as deucravacitinib, versus traditional first-generation biologics has not been characterized in the treatment of scalp psoriasis. This study indirectly compared the long-term efficacy of deucravacitinib versus that of adalimumab for the treatment of scalp psoriasis.
View Article and Find Full Text PDFSafety and efficacy of an intrinsic antitachycardia pacing algorithm in patients from Japan and South Korea: results from a cardiac device registry in the Asia Pacific region.
J Med Econ
December 2025
Department of Cardiology, Severance Hospital, Yonsei University College of Medicine, Seoul, Republic of Korea.
Background: Antitachycardia pacing (ATP) therapy, available in modern implantable cardioverter defibrillators (ICD) and cardiac resynchronization therapy defibrillators (CRT-D), aims to terminate ventricular arrhythmias without administering high energy shocks. The intrinsic ATP (iATP) algorithm automates ATP programming in real-time, tailoring therapy based on previous ATP attempts. This study evaluated the safety, efficacy, and clinical outcomes of iATP in patients from Japan and South Korea.
View Article and Find Full Text PDFIndirect Comparison of Linvoseltamab Versus Teclistamab for the Treatment of Triple-Class Exposed Relapsed/Refractory Multiple Myeloma.
Clin Lymphoma Myeloma Leuk
June 2025
Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY.
Background: B-cell maturation antigen (BCMA) bispecific antibodies have advanced treatment of relapsed/refractory multiple myeloma (RRMM), but comparative data are lacking.
Methods: An unanchored matching-adjusted indirect comparison (MAIC) was conducted between linvoseltamab and teclistamab in triple-class exposed (TCE) RRMM using patient-level data from LINKER-MM1 (117 patients, linvoseltamab 200 mg, data cutoff 1/2024, median follow-up [mFU] 14.3 months) and aggregate data from MajesTEC-1 (165 patients, teclistamab 1.